Plasma-derived VWF/FVIII prophylaxis in children under 6 with VWD: First results from wil-33
Bibliographic record
Abstract
Abstract Introduction: In patients with von Willebrand disease (VWD) and a history of severe and recurrent bleeding, long-term prophylaxis with von Willebrand factor (VWF) concentrate is recommended as standard of care. Efficacy and safety of prophylaxis with a plasma-derived (pd)VWF/factor VIII (FVIII) concentrate in a 1:1 activity ratio (wilate®) has been demonstrated in WIL-31, the largest study in VWD to date. WIL-31 included adults, adolescents and children aged 6 years or older with VWD of all types. Currently, limited data are available for prophylaxis with VWF in pediatric patients under 6 years of age with severe VWD. Aims: To assess the efficacy and safety of prophylaxis with pdVWF/FVIII prophylaxis in children under 6 years old through the first prospective global clinical study. Methods: WIL-33 (NCT04953884) was an open-label, prospective, non-controlled, international, multicenter phase 3 study investigating the efficacy, immunogenicity, and safety of pdVWF/FVIII prophylaxis and pharmacokinetics in pediatric patients under 6 years old with severe VWD (VWF ristocetin cofactor activity [VWF:RCo] <20%). pdVWF/FVIII was administered 2–3 times per week at a recommended dose of 30–50 international units (IU)/kg over 12 months. The primary endpoint was the total annualized bleeding rate (TABR) during prophylaxis. Safety and tolerability were assessed throughout the study. Results: A total of 12 patients were enrolled and treated in this global study. At baseline the median (range) age was 2.0 (1.0–5.0), there were 6 male patients (50%), 4 patients (33.3%) had VWD type 2, and 8 patients (66.7%) had VWD type 3. The per-protocol robustness (PPR) set, a subset of the full analysis set (FAS), excluded three patients with deviations mainly from the recommended dosing. The mean (standard deviation [SD]) TABR in the FAS and PPR set was 4.6 (6.1) and 2.7 (1.8), respectively. The mean (SD) TABR was 2.1 (1.0) and 5.8 (7.2) in patients with VWD type 2 and VWD type 3, respectively in the FAS (PPR: 2.0 [1.1] vs 3.4 [2.2], respectively). Over one third of the total bleeds (22/56; 39%) during prophylaxis in the FAS set were due to allergic rhinitis in one patient. The mean (SD) spontaneous ABR was 0.9 (1.2) in the FAS and 1.0 (1.3) in the PPR set. The median (range) weekly prophylactic dose was 100 (63–311) and 92 (63–130) IU/kg in the FAS and PPR set, respectively. Pharmacokinetic parameters were within the expected ranges. The mean VWF:RCo half-life was 11.7 h. All 45 bleeds treated with pdVWF/FVIII during the prophylaxis period in 10/12 patients in the FAS were successfully managed and rated “excellent”. Most bleeds (95.6%) required only one infusion. Epistaxis was the most frequent bleed type across patients, while joint bleeds were the rarest, with only one bleeding observed in the study. One patient also received wilate® for major surgery during the study, with an overall rating of “excellent” by the hematologist and surgeon. No serious adverse events related to study treatment and no thrombotic events were observed. Conclusion(s): pdVWF/FVIII prophylaxis was efficacious and well tolerated in children under 6 years with severe VWD. WIL-33 is the only prospective clinical trial to specifically investigate prophylaxis in this population.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.001 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.001 |
| Insufficient payload (model declined to judge) | 0.002 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".